Compare NVCR & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVCR | TLRY |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2018 |
| Metric | NVCR | TLRY |
|---|---|---|
| Price | $13.42 | $9.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $28.42 | ★ $150.00 |
| AVG Volume (30 Days) | 1.8M | ★ 20.1M |
| Earning Date | 10-30-2025 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $642,269,000.00 | ★ $830,766,000.00 |
| Revenue This Year | $9.75 | $7.28 |
| Revenue Next Year | $5.62 | $4.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.17 | 2.31 |
| 52 Week Low | $10.70 | $3.51 |
| 52 Week High | $32.06 | $23.20 |
| Indicator | NVCR | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 59.46 |
| Support Level | $12.30 | $9.82 |
| Resistance Level | $13.53 | $15.70 |
| Average True Range (ATR) | 0.54 | 1.49 |
| MACD | 0.09 | -0.23 |
| Stochastic Oscillator | 71.63 | 29.84 |
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.